Satellite Events

12:50-13:50 hours

Hall B

EUSA Pharma​

Raising the Bar in Paediatric Acute Lymphoblastic Leukaemia

Welcome and Introductions
James Whitlock, MD

The impact of hypersensitivity and silent inactivation; What does the evidence tell us? 
Key messages to be covered:
• Evidence confirms that any degree of hypersensitivity to asparaginase means that it is no longer effective
• Masking hypersensitivity could have serious implications for treatment outcomes
James Whitlock, MD

Today’s problems, tomorrow’s solutions; how to overcome the barriers to raising the bar
Key messages to be covered:
• Outcomes from a prospective therapeutic drug-monitoring study
• The lessons learned from implementing therapeutic drug monitoring approach: 
  – How to effect behavioural and infrastructure change
Rob Pieters, MD

Speed is of the essence; Hypersensitivity case study 
Key messages to be covered:
• Substitution of asparaginase should be implemented as soon as hypersensitivity is identified
• Delays (which may be protocol-driven) will extend the period of non-treatment with implications for outcomes
Prof. C Rizzari

Summary and close
James Whitlock, MD

12:50-13:50 hours

Hall B

Takeda: Osteosarcoma Educational Satellite Symposium​

The Osteosarcoma Journey: Progress and Opportunities

Chairman’s Introduction and Reflection: The Osteosarcoma Journey to Date
Dr Bruce Morland
Consultant Paediatric Oncologist & Director of R&D
Birmingham Children’s Hospital, UK

Optimising Outcomes: Capitalising on the Opportunities
Professor Eugenie Kleinerman
Professor and Head, Division of Pediatrics Professor, Department of Cancer Biology
The Mary V. and John A. Reilly Distinguished Chair
University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA

The Future: New Targets
Professor Heribert Jürgens
Director Department of Paediatric Haematology and Oncology, University Children’s Hospital, Münster, Germany


Join SIOP Now!